GH Research (NASDAQ:GHRS) Hits New 12-Month High at $14.66

GH Research PLC (NASDAQ:GHRSGet Free Report) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $14.66 and last traded at $14.55, with a volume of 2674 shares changing hands. The stock had previously closed at $14.09.

Analysts Set New Price Targets

A number of research analysts recently weighed in on GHRS shares. Canaccord Genuity Group raised their price target on shares of GH Research from $30.00 to $31.00 and gave the company a “buy” rating in a research note on Monday, May 6th. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of GH Research in a research note on Tuesday, May 7th. Finally, JMP Securities dropped their price objective on shares of GH Research from $50.00 to $39.00 and set a “market outperform” rating for the company in a research note on Friday, March 1st.

Read Our Latest Research Report on GHRS

GH Research Stock Up 2.4 %

The business has a 50 day simple moving average of $11.81 and a 200-day simple moving average of $8.77.

GH Research (NASDAQ:GHRSGet Free Report) last released its quarterly earnings data on Friday, May 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.07. Sell-side analysts anticipate that GH Research PLC will post -0.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. AdvisorShares Investments LLC lifted its holdings in shares of GH Research by 4.3% in the 4th quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock worth $280,000 after acquiring an additional 1,977 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in GH Research by 14.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 106,363 shares of the company’s stock worth $617,000 after purchasing an additional 13,579 shares in the last quarter. PEAK6 Investments LLC boosted its position in shares of GH Research by 72.9% during the third quarter. PEAK6 Investments LLC now owns 40,308 shares of the company’s stock worth $405,000 after buying an additional 16,991 shares during the period. Barclays PLC grew its stake in shares of GH Research by 98.2% in the third quarter. Barclays PLC now owns 63,590 shares of the company’s stock valued at $640,000 after buying an additional 31,500 shares in the last quarter. Finally, Lynx1 Capital Management LP grew its stake in shares of GH Research by 13.8% in the third quarter. Lynx1 Capital Management LP now owns 1,103,178 shares of the company’s stock valued at $11,087,000 after buying an additional 133,804 shares in the last quarter. Hedge funds and other institutional investors own 56.90% of the company’s stock.

About GH Research

(Get Free Report)

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

Read More

Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.